Home/Filings/4/0001209191-18-021389
4//SEC Filing

Pontifax (Cayman) IV L.P. 4

Accession 0001209191-18-021389

CIK 0001035354other

Filed

Mar 22, 8:00 PM ET

Accepted

Mar 23, 4:16 PM ET

Size

22.7 KB

Accession

0001209191-18-021389

Insider Transaction Report

Form 4
Period: 2018-03-21
Transactions
  • Purchase

    Common Stock

    2018-03-22$8.00/sh+1,600$12,800427,063 total(indirect: By Pontifax Investment Fund)
  • Purchase

    Common Stock

    2018-03-21$7.55/sh+3,255$24,575786,919 total(indirect: By Pontifax Investment Fund)
  • Purchase

    Common Stock

    2018-03-22$8.00/sh+1,441$11,528384,544 total(indirect: By Pontifax Investment Fund)
  • Purchase

    Common Stock

    2018-03-21$7.55/sh+1,585$11,967383,103 total(indirect: By Pontifax Investment Fund)
  • Purchase

    Common Stock

    2018-03-21$7.55/sh+1,760$13,288425,463 total(indirect: By Pontifax Investment Fund)
  • Purchase

    Common Stock

    2018-03-22$8.00/sh+2,959$23,672789,878 total(indirect: By Pontifax Investment Fund)
Transactions
  • Purchase

    Common Stock

    2018-03-21$7.55/sh+3,255$24,575786,919 total(indirect: By Pontifax Investment Fund)
  • Purchase

    Common Stock

    2018-03-21$7.55/sh+1,760$13,288425,463 total(indirect: By Pontifax Investment Fund)
  • Purchase

    Common Stock

    2018-03-22$8.00/sh+1,600$12,800427,063 total(indirect: By Pontifax Investment Fund)
  • Purchase

    Common Stock

    2018-03-21$7.55/sh+1,585$11,967383,103 total(indirect: By Pontifax Investment Fund)
  • Purchase

    Common Stock

    2018-03-22$8.00/sh+1,441$11,528384,544 total(indirect: By Pontifax Investment Fund)
  • Purchase

    Common Stock

    2018-03-22$8.00/sh+2,959$23,672789,878 total(indirect: By Pontifax Investment Fund)
Transactions
  • Purchase

    Common Stock

    2018-03-21$7.55/sh+3,255$24,575786,919 total(indirect: By Pontifax Investment Fund)
  • Purchase

    Common Stock

    2018-03-22$8.00/sh+1,441$11,528384,544 total(indirect: By Pontifax Investment Fund)
  • Purchase

    Common Stock

    2018-03-22$8.00/sh+1,600$12,800427,063 total(indirect: By Pontifax Investment Fund)
  • Purchase

    Common Stock

    2018-03-21$7.55/sh+1,585$11,967383,103 total(indirect: By Pontifax Investment Fund)
  • Purchase

    Common Stock

    2018-03-21$7.55/sh+1,760$13,288425,463 total(indirect: By Pontifax Investment Fund)
  • Purchase

    Common Stock

    2018-03-22$8.00/sh+2,959$23,672789,878 total(indirect: By Pontifax Investment Fund)
Transactions
  • Purchase

    Common Stock

    2018-03-22$8.00/sh+2,959$23,672789,878 total(indirect: By Pontifax Investment Fund)
  • Purchase

    Common Stock

    2018-03-21$7.55/sh+3,255$24,575786,919 total(indirect: By Pontifax Investment Fund)
  • Purchase

    Common Stock

    2018-03-21$7.55/sh+1,760$13,288425,463 total(indirect: By Pontifax Investment Fund)
  • Purchase

    Common Stock

    2018-03-22$8.00/sh+1,441$11,528384,544 total(indirect: By Pontifax Investment Fund)
  • Purchase

    Common Stock

    2018-03-21$7.55/sh+1,585$11,967383,103 total(indirect: By Pontifax Investment Fund)
  • Purchase

    Common Stock

    2018-03-22$8.00/sh+1,600$12,800427,063 total(indirect: By Pontifax Investment Fund)
Transactions
  • Purchase

    Common Stock

    2018-03-21$7.55/sh+1,585$11,967383,103 total(indirect: By Pontifax Investment Fund)
  • Purchase

    Common Stock

    2018-03-21$7.55/sh+3,255$24,575786,919 total(indirect: By Pontifax Investment Fund)
  • Purchase

    Common Stock

    2018-03-21$7.55/sh+1,760$13,288425,463 total(indirect: By Pontifax Investment Fund)
  • Purchase

    Common Stock

    2018-03-22$8.00/sh+1,441$11,528384,544 total(indirect: By Pontifax Investment Fund)
  • Purchase

    Common Stock

    2018-03-22$8.00/sh+2,959$23,672789,878 total(indirect: By Pontifax Investment Fund)
  • Purchase

    Common Stock

    2018-03-22$8.00/sh+1,600$12,800427,063 total(indirect: By Pontifax Investment Fund)
Footnotes (3)
  • [F1]Represents shares of the Issuer held by Pontifax (Cayman) IV L.P. ("Cayman IV"). Pontifax IV GP L.P. ("Pontifax IV") is the general partner of Cayman IV. Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Each of Management 4, Pontifax IV and Cayman IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.
  • [F2]Represents shares of the Issuer held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax IV is the general partner of Israel IV. Management 4 is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Each of Management 4, Pontifax IV and Israel IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.
  • [F3]Represents shares of the Issuer held by Pontifax (China) IV L.P. ("China IV"). Pontifax IV GP L.P. is the general partner of China IV. Management 4 is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by China IV. Each of Management 4, Pontifax IV and China IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

Issuer

Eloxx Pharmaceuticals, Inc.

CIK 0001035354

Entity typeother
IncorporatedCayman Islands

Related Parties

1
  • filerCIK 0001726029

Filing Metadata

Form type
4
Filed
Mar 22, 8:00 PM ET
Accepted
Mar 23, 4:16 PM ET
Size
22.7 KB